Every excipient supplier tracks global market size. Few track which drugs they are actually inside. That gap between macro estimates […]
Excipient Market Share by Drug: The Intelligence Edge Most Pharma Suppliers Are Missing Read Post »
How the five judges who control half of all ANDA litigation are reshaping patent strategy, generic timelines, and drug revenue
The $50 Billion Judicial Variable Big Pharma Can’t Model Away Read Post »
Between 2025 and 2030, roughly $400 billion in annual pharmaceutical revenue becomes legally contestable. That figure is not a projection
The global generic drug market is not growing uniformly. It is concentrating. Between 2025 and 2030, branded drugs accounting for
Why a 20-Year Patent Rarely Means 20 Years of Revenue The statutory term creates a false ceiling. The effective commercial
The $400 Billion Patent Cliff Big Pharma Can’t Avoid Read Post »
For pharma IP teams, portfolio managers, R&D leads, and institutional investors assessing Russia exposure in 2025-2030. The Rouble Economy: Why
Russia Pharma Market Entry: IP Strategy, Patent Risks, and the Localization Playbook Read Post »
The “patent death squad” label has haunted PTAB since 2012. The actual data tells a different story — one where
How PTAB Actually Invalidates Drug Patents — And How to Stop It Read Post »
Combination drugs — pairing a biologic with a small molecule — are among the most commercially valuable assets in pharma.
The global generic drug market will cross $700 billion by 2032. Most of that growth will not come from the
The $700B Generic Drug Opportunity Big Pharma Is Still Getting Wrong Read Post »
Sign in or create a free account to read this DrugPatentWatch article
